| Literature DB >> 33254076 |
Mary E Robbins1, Hye-Youn Cho2, Jason M Hansen3, Joseph R Luchsinger4, Morgan L Locy5, Markus Velten6, Steven R Kleeberger2, Lynette K Rogers7, Trent E Tipple8.
Abstract
Cellular antioxidants protect against hyperoxic lung injury. The role of the glutathione (GSH) system in lung development and bronchopulmonary dysplasia (BPD) pathogenesis has not been systematically investigated. The current study utilized GSH reductase-deficient (Gsr-KO) neonatal mice to test the hypothesis that early disruption of the GSH system negatively impacts lung development and hyperoxic responses. Lungs from wild-type (Gsr-WT) and Gsr-KO mice were analyzed for histopathology, developmental markers, redox indices, and transcriptome profiling at different developmental stages following exposure to room air or hyperoxia (85% O2) for up to 14 d. Lungs from Gsr-KO mice exhibited alveolar epithelial dysplasia in the embryonic and neonatal periods with relatively normal lung architecture in adulthood. GSH and its oxidized form (GSSG) were 50-70% lower at E19-PND14 in Gsr-KO lungs than in age-matched Gsr-WT. Differential gene expression between Gsr-WT and Gsr-KO lungs was analyzed at discrete developmental stages. Gsr-KO lungs exhibited downregulated cell cycle and DNA damage checkpoint genes at E19, as well as lung lipid metabolism and surfactant genes at PND5. In addition to abnormal baseline lung morphometry, Gsr-KO mice displayed a blunted response to hyperoxia. Hyperoxia caused a more robust upregulation of the lung thioredoxin system in Gsr-KO compared to Gsr-WT. Gsr-dependent, hyperoxia-responsive genes were highly associated with abnormal cytoskeleton, skeletal-muscular function, and tissue morphology at PND5. Overall, our data in Gsr-KO mice implicate the GSH system as a key regulator of lung development, cellular differentiation, and hyperoxic responses in neonatal mice.Entities:
Keywords: Bronchopulmonary dysplasia; Embryo; Glutathione reductase; Hyperoxia; Mice; Microarray; Neonate; Thioredoxin
Mesh:
Substances:
Year: 2020 PMID: 33254076 PMCID: PMC7708869 DOI: 10.1016/j.redox.2020.101797
Source DB: PubMed Journal: Redox Biol ISSN: 2213-2317 Impact factor: 11.799
Fig. 1Lung glutathione contents in embryo and newborn wild-type ( (A) Independent effects of genotype and day of life as well as interaction on oxidized (GSH) and (B) reduced disulfide (GSSG) glutathione contents were detected in lung homogenates from newborn Gsr-WT and Gsr-KO mice. (C) GSH/GSSG ratios were subsequently calculated. (D) Calculated GSH redox potential demonstrated independent effects of genotype and day of life as well as interaction between the two. Data are expressed as mean +SEM (*p < 0.05 vs Gsr-WT, n=3–6) and were analyzed by 2-way ANOVA with Tukey's multiple comparison test.
Fig. 2Lung morphology of wild-type ( H&E-stained lungs from Gsr-KO mice (200x) display evidence of septal thickening and alveolar epithelial dysplasia compared to Gsr-WT at embryonic day E19 (A) and persistent septal thickening alveolar epithelial cell dysplasia at PND3 (B) which has essentially normalized by PND56 (C). Bars = 50 μm. Pulmonary function assessment in PND56 mice for pulmonary resistance (D), compliance (E), total lung capacity (F) and airway resistance (G) were assessed. Pulmonary resistance and total lung capacity were significantly decreased in Gsr-KO mice compared to Gsr-WT. (H) Methacholine responses reveal enhanced airway responsiveness in Gsr-KO compared to Gsr-WT at PND 56. Data are expressed as mean +SEM (*p < 0.05 vs Gsr-WT; n=14–18).
Fig. 3Western Blot analyses for T1-alpha (T1α) and surfactant protein C (SP–C) in glutathione reductase-deficient (A) Independent effects of genotype and day of life on lung T1α expression and an interaction between day of life and genotype were detected. (B) No effects or interactions were detected. Data are expressed as mean +SEM (n=3) and were assessed by two-way ANOVA followed by Newman-Keuls post hoc. P < 0.05 *vs E19-Gsr-WT, #vs PND14 Gsr-WT, &vs PND28-Gsr-WT, ∧vs PND70-Gsr-WT, %vs E19-Gsr-KO, @vs PND14-Gsr-KO.
Fig. 4Effect of glutathione reductase (. (A) Venn Diagram analysis determined Gsr-dependently expressed genes at embryonic day E19 and postnatal days 5 (PND5) and PND56. Common Gsr-dependent genes at different developmental ages are shown as same color/pattern blocks in the bar graphs. (B) At E19 (canalicular stage), lungs in Gsr-deficient (Gsr-KO) embryo displayed significantly lowered expression of genes for cell cycle control of chromosomal replication and DNA damage checkpoint regulation and heightened expression of inflammatory and cell death response genes. (C) At PND5 (entering alveolar stage), Gsr-KO lungs showed significantly suppressed transcriptome for lipid metabolism and transport and coagulation system. (D) In mature lung (PND56), Gsr deficiency modulated genes to promote abnormal cardiovascular system function and connective tissue disorders. Analyses were done using GeneSpring (moderated t-test followed by Benjamini-Hochberg multiple testing correction, p < 0.01) and Ingenuity Pathway Analysis software. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Representative glutathione reductase (Gsr)-dependent genes in embryo to adult mouse lungs.
| Category (Age) | RefSeq ID | †FD | Gene Symbol | Gene Title | Functions |
|---|---|---|---|---|---|
| Cell cycle, DNA damage checkpoint regulation (E19) | −3.14 | cell division cycle 6 | DNA replication initiation | ||
| −2.26 | cyclin-dependent kinase 1 | protein complex assembly | |||
| −2.66 | minichromosome maintenance deficient 5 | DNA replication initiation | |||
| −2.41 | aurora kinase A | meiotic spindle organization | |||
| −2.36 | cyclin B1 | mitotic cell cycle | |||
| −2.24 | kinesin family member C1 | mitotic sister chromatid segregation | |||
| Redox and metabolism (E19) | −32.87 | cytochrome P450, family 2, subfamily d, polypeptide 26 | xenobiotic metabolic process | ||
| −25.90 | cytochrome P450, family 2, subfamily c, polypeptide 68 | xenobiotic metabolic process | |||
| −19.54 | carboxypeptidase B2 (plasma) | fibrinolysis | |||
| −18.34 | hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 | lipid metabolism | |||
| −15.45 | apolipoprotein C-II | lipid metabolism | |||
| −12.76 | UDP glucuronosyltransferase 2 family, polypeptide B5 | phase 2 conjugation | |||
| −3.25 | gamma-glutamyltransferase 1 | glutamate metabolic process | |||
| −2.88 | glutathione S-transferase, theta 1 | glutathione metabolic process | |||
| Inflammatory and immunological response (E19) | 3.14 | chitinase-like 3 | polysaccharide catabolic process | ||
| 2.43 | interleukin 33 | leukocyte migration | |||
| 3.66 | interferon-induced protein 44 | immune response | |||
| 6.73 | interferon-induced protein with tetratricopeptide repeats 1 | immune system process, response to virus | |||
| 4.35 | lymphocyte antigen 6 complex, locus C1 | Activation of lymphocytes | |||
| 5.03 | lysophosphatidic acid receptor 3 | activation of MAPK activity | |||
| 2.51 | Fc receptor, IgG, low affinity IV | NK T cell proliferation | |||
| 2.42 | toll-like receptor 4 | innate immune response | |||
| 3.37 | complement component 6 | in utero embryonic development | |||
| Coagulation system/Acute phase response signaling (PND5) | −8.24 | alpha-2-macroglobulin | negative regulation of complement activation | ||
| −21.46 | serine (or cysteine) preptidase inhibitor, clade A, member 1 B | protein N-linked glycosylation | |||
| −39.04 | fibrinogen alpha chain | adaptive immune response | |||
| −9.09 | inter-alpha trypsin inhibitor, heavy chain 3 | peptidase inhibitor activity | |||
| −4.13 | hemopexin | positive regulation of immunoglobulin production | |||
| −6.00 | coagulation factor XIII, beta subunit | blood coagulation pathway | |||
| −23.5 | transthyretin | retinol metabolic process, thyroid hormone transport | |||
| Lipid metabolism (PND5) | −4.54 | apolipoprotein C-II | lipid transport | ||
| −16.65 | apolipoprotein A-I | lipid transporter activity | |||
| −27.57 | albumin | fatty acid binding, transport | |||
| −8.44 | alpha 1 microglobulin | protein-chromophore linkage | |||
| Angiogenesis, connective tissue disorder (PND56) | −2.54 | neuron-derived neurotrophic factor | angiogenesis | ||
| −2.25 | proline arginine-rich end leucine-rich repeat | axonogenesis | |||
| −1.87 | collagen, type IV, alpha 3 | negative regulation of angiogenesis | |||
| −1.86 | transforming growth factor, beta receptor II | patterning of blood vessels |
†Fold difference of baseline lung gene expression between Gsr-WT and Gsr-KO mice at the designated age (negative values indicate lowered expression in Gsr-KO than in Gsr-WT, positive values indicate heightened expression in Gsr-KO than in Gsr-WT). Full lists of the significantly varied genes between two genotypes determined by moderated t-test (p < 0.01) are in Supplementary Tables S1–S3. E=embryonic day. PND=postnatal day.
Fig. 5Effects of neonatal hyperoxic exposure on glutathione reductase-sufficient ( (A) H&E-stained lung sections (200x) from PND14 Gsr-WT and Gsr-KO neonates exposed to room air (FiO2 0.21) or hyperoxia (FiO2 0.85) for 14 d (PND0-14). Characteristic alveolar simplification is present in hyperoxia-exposed Gsr-WT mice while evidence of persistent alveolar epithelial dysplasia remains in Gsr-KO mice after hyperoxia exposure. (B) Independent effects of and an interaction between hyperoxia and genotype on alveolar number and perimeter. Data are expressed as mean +SEM (n=3–5). *p < 0.05 vs Gsr-WT/Room Air. **p < 0.05 vs Gsr-KO/Room Air. Bars = 50 μm.
Fig. 6Effects of glutathione reductase (Gsr) deficiency and hyperoxia on the pulmonary thioredoxin (TXN) system at PND7. Protein levels of TXN1, TXN reductase 1 (Txnrd1), and TXN2 normalized by actin levels in wild-type (Gsr-WT) and Gsr-deficient (Gsr-KO) neonatal mice. 2-Way ANOVA followed by Tukey's post hoc revealed an effect of genotype and exposure on the expression of all three proteins, as well as an interaction on TXNRD1 and TXN2 expression. Data expressed as mean +SEM (n=3), p < 0.05 *vs Gsr-WT/0.21, #vs Gsr-KO/0.21, &vs Gsr-WT/0.85.
Fig. 7Effects of glutathione reductase (Gsr) deficiency and hyperoxia (85% O) on lung transcriptomics. (A) Heat map from hierarchical clustering analysis depicts lung expression profiles of Gsr-dependently hyperoxia (0.85 FiO2)-responded genes at postnatal day 5 (PND5) after hyperoxia exposure (PND0-PND5, n = 303, 2-way ANOVA with p < 0.01). Color bar indicates average expression intensity (n = 3/group) normalized to wild-type (Gsr-WT)-Air (0.21 FiO2) group. Venn Diagram analysis depicted number of genotype-specific hyperoxia responsive genes determined by moderated t-test in Gsr-WT and Gsr-deficient (Gsr-KO) neonates. (B) Hyperoxia altered lung genes involved predominantly in cytoskeleton and skeletal/muscular development and tissue and cell morphology in Gsr-KO neonates. (C) The key molecular network of the Gsr-dependently altered neonatal lung genes by hyperoxia was cytoskeleton and skeletal-muscular function and tissue morphology and development. (D) Hyperoxia-altered genes in Gsr-KO neonates may inhibit respiratory failure and neonatal death through activation of upstream molecules such as myogenic differentiation 1 (Myod1) and β-catennin (CTNNB1). (E) Venn Diagram analysis depicted number of genotype-specific hyperoxia responsive genes following recovery from neonatal hyperoxia recovery within Gsr-WT and Gsr-KO adult mice. (F) Neonatally exposed hyperoxia was predicted to inhibit genes involved in lipid metabolism (e.g., bile acid, cholesterol) and enhance genes involved in transcription of adulthood lungs in Gsr-KO mice. Analysis was done by GeneSpring and Ingenuity Pathway Analysis software. Molecules colored by expression levels of Gsr-KO/0.85 FiO2 at PND5 (vs Gsr-WT/0.85 FiO2). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Representative glutathione reductase (Gsr)-dependent neonate lung genes regulated by hyperoxia exposed during postnatal days (PND0-PND5).
| RefSeq ID | ¶FD | Gene Symbol | Gene Title | |||
|---|---|---|---|---|---|---|
| 0.001502453 | −5.40 | 34.61 | 36.03 | keratin 13 | ||
| 7.66E-04 | −4.69 | 20.55 | 21.29 | keratin 4 | ||
| 0.0081382 | −1.69 | 48.45 | 19.19 | myosin, heavy polypeptide 8, skeletal muscle, perinatal | ||
| 0.001268343 | −2.70 | 7.90 | 9.26 | calmodulin-like 3 | ||
| 0.005731548 | −1.50 | 21.62 | 7.56 | actin, alpha 1, skeletal muscle | ||
| 3.51E-04 | −1.34 | 8.05 | 5.92 | Rho GTPase activating protein 36 | ||
| 0.001839206 | −2.15 | 4.21 | 5.20 | cysteine-rich C-terminal 1 | ||
| 0.008994052 | −2.29 | 4.52 | 4.92 | prostate stem cell antigen | ||
| 0.0049872 | −1.91 | 4.34 | 4.90 | interferon induced protein with tetratricpeptide repeats 1 B like 1 | ||
| 0.006323175 | −1.12 | 6.94 | 4.67 | actinin alpha 3 | ||
| 0.007458202 | −2.65 | 4.38 | 4.64 | small proline-rich protein 2A1, etc. | ||
| 0.002655688 | −1.90 | 5.58 | 4.51 | cystatin A1 | ||
| 0.0084611 | −1.54 | 3.61 | 4.50 | cartilage intermediate layer protein, nucleotide pyrophosphohydrolase | ||
| 0.001477798 | −1.80 | 3.55 | 4.22 | desmocollin 2 | ||
| 0.001027153 | −1.15 | 4.35 | 4.05 | calcium channel, voltage-dependent, gamma subunit 1 | ||
| 0.008563787 | −1.37 | 3.87 | 3.54 | myogenic factor 6 | ||
| 0.003077287 | −1.92 | 3.02 | 3.29 | cornifelin | ||
| 0.004109589 | −1.44 | 2.83 | 3.27 | leiomodin 3 (fetal) | ||
| 0.0016160 | −1.41 | 2.92 | 3.17 | keratinocyte differentiation associated protein | ||
| 0.004861059 | −1.15 | 3.82 | 3.12 | ryanodine receptor 1, skeletal muscle | ||
| 0.0023872 | −1.31 | 3.12 | 2.90 | cytochrome P450, family 2, subfamily a, polypeptide 4 | ||
| 0.004647014 | −9.79 | −1.18 | −1.59 | pregnancy zone protein | ||
| 0.008516206 | 1.42 | −19.17 | −1.52 | natriuretic peptide type A | ||
| 0.0036717 | 1.20 | −1.30 | −1.36 | eosinophil-associated, ribonuclease A family, member 1 | ||
| 0.006182605 | 1.41 | −1.01 | −1.32 | suppressor of cytokine signaling 3 | ||
| 0.007889654 | −5.05 | 1.04 | −1.32 | retinol dehydrogenase 7 | ||
| 0.0063489 | 1.27 | −1.01 | −1.27 | mitochondrial calcium uptake family, member 3 |
¶Fold difference of gene expression between Gsr-WT and Gsr-KO mice at the end of 5-day hyperoxia exposure at PND5 (negative values indicate lower expression in Gsr-KO than in Gsr-WT, positive values indicate higher expression in Gsr-KO than in Gsr-WT). Full lists of the Gsr-dependently varied neonatal lung genes by hyperoxia (n=303, 2-way ANOVA p < 0.01) are in Supplementary Table S4.
Fold change after 5-day hyperoxia exposure in Gsr-WT or in Gsr-KO over genotype-matched air-exposed controls (negative values indicate decreased expression by hyperoxia, positive values indicate increased expression by hyperoxia).
Representative glutathione reductase (Gsr)-dependent lung genes at postnatal day 56 (PND56) after neonatal hyperoxia exposure.
| RefSeq ID | ¶FD | Gene Symbol | Gene Title | |||
|---|---|---|---|---|---|---|
| 0.00457 | −1.73 | 2.26 | 4.13 | cytochrome P450, family 26, subfamily b, polypeptide 1 | ||
| 0.001644 | −1.30 | 1.03 | 1.49 | dynein light chain Tctex-type 1, pseuodogene 1///dynein light chain Tctex-type 1A | ||
| 4.38E-04 | −1.91 | 1.12 | 1.49 | zinc finger and BTB domain containing 7a | ||
| 5.83E-04 | −1.21 | 1.30 | 1.42 | vasohibin 2 | ||
| 4.96E-05 | −1.15 | 1.32 | 1.36 | ribosomal protein S6 kinase-like 1 | ||
| 0.004434 | −1.30 | 1.22 | 1.35 | 3-oxoacid CoA transferase 2A | ||
| 0.005966 | 5.21 | 1.32 | −1.81 | chemokine (C-X-C motif) ligand 3 | ||
| 0.005792 | 1.09 | −3.33 | −1.76 | myosin, light polypeptide 2, regulatory, cardiac, slow | ||
| 6.16E-04 | 1.36 | −1.15 | −1.47 | chymase 1, mast cell | ||
| 0.00933 | 1.42 | −1.26 | −1.47 | transmembrane protein 156 | ||
| 6.26E-04 | 1.35 | −1.16 | −1.43 | astrotactin 2 | ||
| 0.002129 | 1.18 | −1.41 | −1.40 | methyltransferase like 14 | ||
| 0.003614 | 2.65 | 1.24 | −1.27 | chemokine (C-X-C motif) ligand 2 | ||
| 0.006028 | 1.88 | 1.23 | −1.36 | solute carrier family 5 (sodium/glucose cotransporter), member 1 | ||
| 0.008386 | 1.59 | −1.09 | −1.35 | repetin | ||
| 0.008755 | 1.08 | −1.63 | −1.13 | keratin associated protein 17-1 | ||
| 3.89E-06 | 1.18 | −1.48 | −1.12 | secretogranin V |
¶Fold difference of lung gene expression between Gsr-WT and Gsr-KO mice at PND56 after neonatal hyperoxia exposure (negative values indicate lower expression in hyperoxia-PND56 Gsr-KO than in hyperoxia-PND56 Gsr-WT, positive values indicate higher expression in hyperoxia-PND56 Gsr-KO than in hyperoxia-PND56 Gsr-WT). Full lists of the Gsr-dependently varied lung genes during recovery after neonate hyperoxia exposure (n=491, 2-way ANOVA p < 0.01) are in Supplementary Table S8.
Fold change in PND56 lung after neonate-hyperoxia exposure compared to neonate-air exposure in each genotype (negative values indicate decreased expression in neonate hyperoxia-exposed lung than in neonate air-exposed lung, positive values indicate increased expression in neonate hyperoxia-exposed lung than in neonate air-exposed lung).